Weekly Spotlight - 27.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Market Growth for Microscopic Polyangiitis Treatments to Surge by 2023-2032, According to DelveInsight Report

The microscopic polyangiitis market is expected to grow significantly from 2023 to 2032, driven by advancements in treatments and increased awareness. Companies like Novartis, Genentech, Vifor Pharma, Inflarx GmbH, GlaxoSmithKline, and Roche are developing new therapies to address this condition. DelveInsight's analysis highlights the potential for improved patient outcomes and market expansion.

Gene Variants Linked to Higher Mortality Risk in AAV Patients

Research has identified variants of the SERPINA1 gene that are associated with an increased risk of death in patients with ANCA-associated vasculitis, including those with microscopic polyangiitis. These genetic variations could help predict patient outcomes and guide treatment strategies.

Rituximab and Cyclophosphamide Show Similar Efficacy in Treating AAV in Children

A study compares the effectiveness of rituximab and cyclophosphamide in treating ANCA-associated vasculitis, in children. The results show that both medications have similar efficacy in managing the disease, offering alternative treatment options for young patients.